Increasing Prevalence of Asthma and COPD: The rising incidence of asthma and chronic obstructive pulmonary disease (COPD) ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...
Inhaled nitric oxide market thrives on neonatal expansions, portable system breakthroughs, and precise dosing innovations.
For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...
More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).
Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback